vs
Side-by-side financial comparison of Belpointe PREP, LLC (OZ) and Instil Bio, Inc. (TIL). Click either name above to swap in a different company.
Belpointe PREP, LLC is the larger business by last-quarter revenue ($3.1M vs $2.2M, roughly 1.4× Instil Bio, Inc.). Instil Bio, Inc. runs the higher net margin — -365.3% vs -380.8%, a 15.5% gap on every dollar of revenue. On growth, Belpointe PREP, LLC posted the faster year-over-year revenue change (180.1% vs -19.2%).
Instil Bio Inc. is a clinical-stage biotechnology company focused on developing innovative tumor-infiltrating lymphocyte (TIL) therapies for patients with difficult-to-treat advanced solid tumors. It operates in the immuno-oncology segment, serving patient populations that show limited response to existing standard cancer treatment options.
OZ vs TIL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.1M | $2.2M |
| Net Profit | $-11.7M | $-8.2M |
| Gross Margin | — | — |
| Operating Margin | — | -426.3% |
| Net Margin | -380.8% | -365.3% |
| Revenue YoY | 180.1% | -19.2% |
| Net Profit YoY | -41.8% | 31.1% |
| EPS (diluted) | $-3.10 | $-1.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.1M | $2.2M | ||
| Q3 25 | $2.4M | $2.2M | ||
| Q2 25 | $2.0M | $2.2M | ||
| Q1 25 | $1.7M | $2.2M | ||
| Q4 24 | $1.1M | $2.8M | ||
| Q3 24 | $860.0K | $1.5M | ||
| Q2 24 | $384.0K | $0 | ||
| Q1 24 | $337.0K | $0 |
| Q4 25 | $-11.7M | $-8.2M | ||
| Q3 25 | $-12.1M | $-13.6M | ||
| Q2 25 | $-7.6M | $-21.4M | ||
| Q1 25 | $-8.6M | $-28.2M | ||
| Q4 24 | $-8.2M | $-11.9M | ||
| Q3 24 | $-6.9M | $-23.0M | ||
| Q2 24 | $-4.7M | $-14.9M | ||
| Q1 24 | $-4.0M | $-24.3M |
| Q4 25 | — | -426.3% | ||
| Q3 25 | — | -670.0% | ||
| Q2 25 | — | -1045.5% | ||
| Q1 25 | — | -1363.2% | ||
| Q4 24 | — | -426.1% | ||
| Q3 24 | — | -1582.8% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -380.8% | -365.3% | ||
| Q3 25 | -509.3% | -606.0% | ||
| Q2 25 | -381.0% | -954.2% | ||
| Q1 25 | -495.6% | -1257.8% | ||
| Q4 24 | -752.0% | -428.8% | ||
| Q3 24 | -805.6% | -1541.9% | ||
| Q2 24 | -1229.2% | — | ||
| Q1 24 | -1181.3% | — |
| Q4 25 | $-3.10 | $-1.13 | ||
| Q3 25 | $-3.21 | $-2.01 | ||
| Q2 25 | $-2.06 | $-3.24 | ||
| Q1 25 | $-2.35 | $-4.32 | ||
| Q4 24 | $-2.26 | $-1.82 | ||
| Q3 24 | $-1.90 | $-3.54 | ||
| Q2 24 | $-1.30 | $-2.29 | ||
| Q1 24 | $-1.10 | $-3.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.3M | $6.6M |
| Total DebtLower is stronger | $260.6M | — |
| Stockholders' EquityBook value | — | $113.9M |
| Total Assets | $564.2M | $203.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.3M | $6.6M | ||
| Q3 25 | $29.6M | $5.8M | ||
| Q2 25 | $25.0M | $7.7M | ||
| Q1 25 | $23.0M | $15.4M | ||
| Q4 24 | $24.7M | $8.8M | ||
| Q3 24 | $24.0M | $6.7M | ||
| Q2 24 | $24.7M | $6.8M | ||
| Q1 24 | $29.2M | $5.5M |
| Q4 25 | $260.6M | — | ||
| Q3 25 | $251.4M | — | ||
| Q2 25 | $228.4M | — | ||
| Q1 25 | $203.3M | — | ||
| Q4 24 | $177.0M | — | ||
| Q3 24 | $144.1M | — | ||
| Q2 24 | $119.9M | — | ||
| Q1 24 | $86.9M | — |
| Q4 25 | — | $113.9M | ||
| Q3 25 | — | $120.4M | ||
| Q2 25 | — | $131.7M | ||
| Q1 25 | — | $144.9M | ||
| Q4 24 | — | $169.4M | ||
| Q3 24 | — | $176.3M | ||
| Q2 24 | — | $195.0M | ||
| Q1 24 | — | $205.8M |
| Q4 25 | $564.2M | $203.5M | ||
| Q3 25 | $570.8M | $211.8M | ||
| Q2 25 | $556.8M | $231.0M | ||
| Q1 25 | $537.4M | $237.4M | ||
| Q4 24 | $517.6M | $263.6M | ||
| Q3 24 | $495.7M | $272.6M | ||
| Q2 24 | $476.2M | $294.3M | ||
| Q1 24 | $450.9M | $306.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.2M | $-7.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-25.2M | $-7.1M | ||
| Q3 25 | $-6.0M | $-10.6M | ||
| Q2 25 | $-2.4M | $-14.8M | ||
| Q1 25 | $-6.6M | $-4.2M | ||
| Q4 24 | $-13.7M | $-10.6M | ||
| Q3 24 | $-3.3M | $-20.1M | ||
| Q2 24 | $1.2M | $-10.6M | ||
| Q1 24 | $-6.6M | $-14.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
